Medications

US approves Sanofi, Regeneron arthritis drug

US federal regulators have given the green light to French pharmaceutical company Sanofi and its US partner Regeneron to market a drug to treat the chronic inflammatory condition, rheumatoid arthritis.

Arthritis & Rheumatism

Most part D plans cover at least one biologic DMARD

(HealthDay)—Although most Medicare Part D plans cover at least one biologic disease-modifying antirheumatic drug (DMARD), copayments are high, according to a study published in the June issue of Arthritis & Rheumatology.

Medications

FDA panel supports continued testing of pain drugs

(AP) -- A panel of arthritis experts has recommended that the federal government allow continued testing of an experimental class of pain drugs for arthritis, despite links to bone decay and joint failure

page 18 from 24